US20030180346A1 - Silver containing wound dressing - Google Patents

Silver containing wound dressing Download PDF

Info

Publication number
US20030180346A1
US20030180346A1 US10/311,674 US31167402A US2003180346A1 US 20030180346 A1 US20030180346 A1 US 20030180346A1 US 31167402 A US31167402 A US 31167402A US 2003180346 A1 US2003180346 A1 US 2003180346A1
Authority
US
United States
Prior art keywords
fibre
wound dressing
silver
weight
dressing according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/311,674
Inventor
David Woods
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Convatec Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9899858&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20030180346(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Assigned to ACORDIS SPECIALITY FIBRES LIMITED reassignment ACORDIS SPECIALITY FIBRES LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: WOODS, DAVID MALCOLM
Publication of US20030180346A1 publication Critical patent/US20030180346A1/en
Assigned to CONVATEC LIMITED reassignment CONVATEC LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ACORDIS SPECIALITY FIBRES LIMITED
Assigned to J.P. MORGAN EUROPE LIMITED reassignment J.P. MORGAN EUROPE LIMITED SECURITY AGREEMENT Assignors: CONVATEC LIMITED
Assigned to CONVATEC LIMITED reassignment CONVATEC LIMITED RELEASE OF SECURITY INTEREST AT 021901/0518 Assignors: J.P. MORGAN EUROPE LIMITED
Assigned to JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT reassignment JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT SECURITY AGREEMENT Assignors: CONVATEC LIMITED
Assigned to JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT reassignment JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT AMENDED AND RESTATED SECURITY AGREEMENT Assignors: CONVATEC LIMITED
Priority to US13/767,656 priority Critical patent/US8728513B2/en
Priority to US14/280,512 priority patent/US9066989B2/en
Priority to US14/696,216 priority patent/US9345805B2/en
Priority to US15/162,890 priority patent/US10010647B2/en
Assigned to CONVATEC TECHNOLOGIES, INC., UNOMEDICAL A/S, UNOMEDICAL LIMITED, CONVATEC LIMITED reassignment CONVATEC TECHNOLOGIES, INC. RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: JPMORGAN CHASE BANK, N.A.
Priority to US16/005,467 priority patent/US10391197B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42Use of materials characterised by their function or physical properties
    • A61L15/46Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/18Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing inorganic materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/28Polysaccharides or their derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42Use of materials characterised by their function or physical properties
    • A61L15/44Medicaments
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0023Polysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0052Mixtures of macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061Use of materials characterised by their function or physical properties
    • A61L26/0066Medicaments; Biocides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/10Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
    • A61L2300/102Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
    • A61L2300/104Silver, e.g. silver sulfadiazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404Biocides, antimicrobial agents, antiseptic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/42Anti-thrombotic agents, anticoagulants, anti-platelet agents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/24Structurally defined web or sheet [e.g., overall dimension, etc.]
    • Y10T428/24033Structurally defined web or sheet [e.g., overall dimension, etc.] including stitching and discrete fastener[s], coating or bond
    • Y10T428/24041Discontinuous or differential coating, impregnation, or bond
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/249921Web or sheet containing structurally defined element or component
    • Y10T428/249924Noninterengaged fiber-containing paper-free web or sheet which is not of specified porosity
    • Y10T428/249928Fiber embedded in a ceramic, glass, or carbon matrix
    • Y10T428/249929Fibers are aligned substantially parallel
    • Y10T428/24993Fiber is precoated
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T442/00Fabric [woven, knitted, or nonwoven textile or cloth, etc.]
    • Y10T442/20Coated or impregnated woven, knit, or nonwoven fabric which is not [a] associated with another preformed layer or fiber layer or, [b] with respect to woven and knit, characterized, respectively, by a particular or differential weave or knit, wherein the coating or impregnation is neither a foamed material nor a free metal or alloy layer
    • Y10T442/2525Coating or impregnation functions biologically [e.g., insect repellent, antiseptic, insecticide, bactericide, etc.]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T442/00Fabric [woven, knitted, or nonwoven textile or cloth, etc.]
    • Y10T442/40Knit fabric [i.e., knit strand or strip material]
    • Y10T442/475Including a free metal or alloy constituent
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T442/00Fabric [woven, knitted, or nonwoven textile or cloth, etc.]
    • Y10T442/40Knit fabric [i.e., knit strand or strip material]
    • Y10T442/475Including a free metal or alloy constituent
    • Y10T442/481Chemically deposited metal layer [e.g., chemical precipitation or electrochemical deposition or plating, etc.]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T442/00Fabric [woven, knitted, or nonwoven textile or cloth, etc.]
    • Y10T442/60Nonwoven fabric [i.e., nonwoven strand or fiber material]
    • Y10T442/654Including a free metal or alloy constituent
    • Y10T442/655Metal or metal-coated strand or fiber material

Definitions

  • This invention relates to a wound dressing, in particular to a wound dressing having antimicrobial activity.
  • European Patent Application No. 707,793 discloses a silver-containing antimicrobial agent which comprises carboxymethylcellulose containing silver in an amount of 0.02 to 1 percent by weight and having a degree of substitution of at least 0.4.
  • Japanese Published Unexamnined Patent Application 11-001,895 discloses a hygienic product such as a disposable diaper, sanitary napkin or incontinence pad which comprises water-insoluble carboxymethylcellulose (derived from woodpulp) containing 0.32% by weight silver ions.
  • the first fibre is preferably substantially insoluble in water and preferably comprises a sodium carboxyinethylcellulose fibre, an alginate fibre, a chitosan or chitosan derivative fibre or an acrylic fibre.
  • the fibre is a carboxymethylcellulose fibre, it preferably has a degree of substitution between 0.1 and 0.4.
  • the fibre is an acrylic fibre, it is preferably an acrylic fibre which incorporates a comonomer such as itaconic acid or 2-acrylamido methyl propane sulphonic acid to provide dye-sites in the fibre.
  • Wound dressings in which the first fibre is a carboxymethylcellulose fibre are particularly preferred.
  • the second fibre may be similar or different to the first fibre. Similar fibres are preferably used.
  • the second fibre should be such as not to discolour to an objectionable degree in light, and as such should, for example, contain no silver or such low levels of silver that it does not discolour at all or discolours only to an degree which is not objectionable aesthetically.
  • the silver ions are preferably introduced into the first CMC fibre by ion-exchange, for example by contacting CMC with an aqueous solution of a salt such as, silver(I) nitrate.
  • a salt such as, silver(I) nitrate.
  • CMC often contains sodium chloride as a by product of the reaction between cellulose and chloroacetic acid and as silver chloride is highly insoluble. It maybe preferred to perform the ion-exchange reaction on a salt free grade of CMC. It is preferred that the balance of the carboxyl groups in the CMC be neutralised with sodium ions.
  • the CMC is preferably derived from lyocell, as disclosed for example in WO 93/12275, WO 94/16746 and PCT/GB99/02093.
  • the fibrous CMC is preferably in the form of staple fibre or continuous filament yarn. It is preferably contained within a textile article such as a woven, knitted or most preferably a nonwoven fabric, such as a needlepunched nonwoven fabric.
  • the dressings of the invention are preferably gel-forming, which makes them advantageously low-adherent to wounds and consequently easy to remove. They are soft, conformable and absorbent. Silver metal ions are released slowly over an extended period of time from a wetted dressing of the invention.
  • the second fibre which does not contain silver is preferably also CMC, but other kinds of gel-forming fibre or of textile fibre may also be utilised. If the dressings are blended from unexposed fibre, on exposure to light, such dressings develop either a speckled appearance or a light brown or light grey colour which is not unsightly. However, it is preferred to pre-expose the silver-containing fibre to light before blending, so that after blending the dressing is light stable and the uniformity of blending can be checked visually.
  • wound dressings of the invention are useful in the treatment of infected wounds, and as a prophylactic measure against infection of uninfected wounds, also for the reduction or elimination of unpleasant odours produced by wounds.
  • Blending was accomplished by carrying out a carding operation twice to achieve a uniform blend, on hand pre-mixed fibre.
  • the carded web was then cross-folded to give the desired basis weight.
  • the web was then bonded on a needle loom to give a coherent web from which individual dressings were cut.
  • a conventional carboxymethyl cellulose fibre control sample was manufactured by the same method.
  • the master batch material was produced by the soaking of CMC fibre tow in silver nitrate and the absorbency tests were first of all carried out on tow using a free swell test. It was found that the CMC fibre control had an absorbency of 28 g/g and the silver CMC had an absorbency of 30 g/g. These differences were not considered to be significant.
  • the wound treatment products utilising the invention are unlikely to be left on a wound for more than a few days, and certainly no more than a week, so that it an be seen that a blend containing 0.5% silver retains its efficiency in terms of antimicrobial effect for at least twice the period that would be required in practice.
  • a solution of water (33.1 g) and industrial methylated spirit (IMS) (36.0 g) was made up in a black glass bottle suitable for rolling on a bottle roller. To it was added silver nitrate (30.0 g) and the latter was stirred until it dissolved. No heat was required. To this solution was added 12g of high manuronic calcium alginate tow and the whole was rolled on a bottle roller for four hours. After this period of time the tow was removed and washed in a solution (70 g) containing IMS and water as a 50/50 mixture.
  • IMS industrial methylated spirit
  • Soft finish in the form of polysorbate 20 (0.7 g) was dissolved in (70 g) solution of IMS/water as a 95/5 mixture and the tow was soaked in this medium for approximately 50 minutes. The silver alginate master batch was then dried in a fume cupboard to give a product having 13.7% of silver overall on the fibre.
  • the diluted silver alginate fibre was then carded, cross-folded and needled into a non-woven web. By calculation the final product would contain silver at an average level of 0.6%. It had a light grey-brown flecked mottled appearance.
  • the invention also contemplates multiple layer dressings some or all of which layers may comprise blended product incorporated silver additions.
  • a silver containing blended layer of a non-gel forming fibre such as a silver containing acrylic fibre blended with pure acrylic fibre could be faced with a wound contact layer of a gel forming fibre.
  • An example of the contact layer could be an alginate fibre and the alginate layer could be blended with a silver added fibre or may have no silver at all, being a simple gel forming alginate fibre.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Materials For Medical Uses (AREA)
  • Nonwoven Fabrics (AREA)
  • Artificial Filaments (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)

Abstract

A wound dressing having anti-microbial activity comprises a first fibre capable of bonding with silver (1) cations. The wound dressing comprises a blend of the first fibre to which silver (1) cations are bonded and a second fibre which is substantially free from silver. The wound dressing comprises from 0.01 to 5.0 percent by weight of silver (1) cations, based on the weight of fibre.

Description

  • This invention relates to a wound dressing, in particular to a wound dressing having antimicrobial activity. [0001]
  • International Patent Applications WO 93/12275, WO 94/16746 and PCT/GB99/02093 disclose the carboxymethylation of lyocell fibre and the use of such carboxymethylated fibre in wound dressings. [0002]
  • European Patent Application No. 707,793 discloses a silver-containing antimicrobial agent which comprises carboxymethylcellulose containing silver in an amount of 0.02 to 1 percent by weight and having a degree of substitution of at least 0.4. [0003]
  • Japanese Published Unexamnined Patent Application 11-001,895 discloses a hygienic product such as a disposable diaper, sanitary napkin or incontinence pad which comprises water-insoluble carboxymethylcellulose (derived from woodpulp) containing 0.32% by weight silver ions. [0004]
  • The silver-containing fibre used in the prior art dressings discolour (turn dark brown or black) on exposure to light. In consequence, such dressings may exhibit an unsightly appearance. Attempts have been made to overcome this problem and are described for example in International Patent Application WO 00/90173. [0005]
  • It is an object of the present invention to provide a wound dressing in which the above disadvantages are reduced or substantially obviated. [0006]
  • The present invention provides a wound dressing having anti-microbial activity, which comprises a first fibre capable of bonding with silver ([0007] 1) cations, characterised in that the wound dressing comprises a blend of the first fibre to which silver (1) cations are bonded and a second fibre which is substantially free from silver.
  • The wound dressing according to the invention preferably comprises from 0.01 to 5%, more preferably from 0.1 to 4%, even more preferably from 0.25 to 3% by weight of silver ([0008] 1) cations, based on the weight of fibre. Most preferably, the wound dressing contains 1 to 2% by weight based on fibre, of silver (1) cations, where the fibre is carboxymethyl cellulose fibre and 0.25% to 0.75% silver (1) cations, where the fibre is an alginate fibre by weight based on the weight of fibre, of silver (1) cations.
  • The first fibre is preferably substantially insoluble in water and preferably comprises a sodium carboxyinethylcellulose fibre, an alginate fibre, a chitosan or chitosan derivative fibre or an acrylic fibre. Where the fibre is a carboxymethylcellulose fibre, it preferably has a degree of substitution between 0.1 and 0.4. Where the fibre is an acrylic fibre, it is preferably an acrylic fibre which incorporates a comonomer such as itaconic acid or 2-acrylamido methyl propane sulphonic acid to provide dye-sites in the fibre. [0009]
  • Where the fibre is an alginate fibre, it may be a calcium alginate fibre or a mixed metal alginate fibre such as a calcium/sodium alginate fibre. The alginate polyemr amy be one with a high mannuoronate or a high guluronate. [0010]
  • Wound dressings in which the first fibre is a carboxymethylcellulose fibre are particularly preferred. The second fibre may be similar or different to the first fibre. Similar fibres are preferably used. The second fibre should be such as not to discolour to an objectionable degree in light, and as such should, for example, contain no silver or such low levels of silver that it does not discolour at all or discolours only to an degree which is not objectionable aesthetically. [0011]
  • The ratio of the first silver-containing fibre to the second fibre is preferably in the range from 0.5 to 25% by weight, more preferably 5 to 20% by weight, of the total weight of the fibre [0012]
  • In order to achieve the desired overall concentration of silver ions, the first fibre preferably includes about 10% by weight, based on the weight of fibre, of silver ([0013] 1) cations and is blended with a large proportion of unsilvered fibre so as to give a blended product containing the desired weight of silver. The silver ions are preferably chemically bonded to the first fibre.
  • As specified above, the degree of substitution (D.S.) of the sodium carboxymethylcellulose (CMC) is preferably at least 0.1, and is preferably less than 0.4. Such CMC is inherently insoluble in water and also in saline solution. A higher D.S. gives at least partial solubility in water, which is undesirable in the field to which the invention relates. The D.S. is more preferably in the range from 0.20 to 0.35, for example about 0.3. [0014]
  • The silver ions are preferably introduced into the first CMC fibre by ion-exchange, for example by contacting CMC with an aqueous solution of a salt such as, silver(I) nitrate. As CMC often contains sodium chloride as a by product of the reaction between cellulose and chloroacetic acid and as silver chloride is highly insoluble. It maybe preferred to perform the ion-exchange reaction on a salt free grade of CMC. It is preferred that the balance of the carboxyl groups in the CMC be neutralised with sodium ions. [0015]
  • The CMC is preferably derived from lyocell, as disclosed for example in WO 93/12275, WO 94/16746 and PCT/GB99/02093. [0016]
  • The fibrous CMC is preferably in the form of staple fibre or continuous filament yarn. It is preferably contained within a textile article such as a woven, knitted or most preferably a nonwoven fabric, such as a needlepunched nonwoven fabric. [0017]
  • The dressings of the invention are preferably gel-forming, which makes them advantageously low-adherent to wounds and consequently easy to remove. They are soft, conformable and absorbent. Silver metal ions are released slowly over an extended period of time from a wetted dressing of the invention. [0018]
  • The second fibre which does not contain silver is preferably also CMC, but other kinds of gel-forming fibre or of textile fibre may also be utilised. If the dressings are blended from unexposed fibre, on exposure to light, such dressings develop either a speckled appearance or a light brown or light grey colour which is not unsightly. However, it is preferred to pre-expose the silver-containing fibre to light before blending, so that after blending the dressing is light stable and the uniformity of blending can be checked visually. [0019]
  • The wound dressings of the invention may contain other medicaments if desired. [0020]
  • The wound dressings of the invention are useful in the treatment of infected wounds, and as a prophylactic measure against infection of uninfected wounds, also for the reduction or elimination of unpleasant odours produced by wounds.[0021]
  • The invention is illustrated by the following Examples, in which parts and proportions are by weight unless otherwise specified. [0022]
  • EXAMPLE 1
  • Manufacture of Master Batch Material [0023]
  • The optimum conditions for manufacture of a master batch material were determined as follows: [0024]
  • Sodium carboxy methyl cellulose fibre (CMC), Hydrocel®, available from Acordis Speciality Fibres Limited of Coventry England, was soaked in silver nitrate (AgNO[0025] 3) solution in 50 volume % industrial methylated spirit/50 volume % water and the following table shows the percentage silver take-up after soakin, as measured by x-ray fluorescence.
    % AgNO3
    Conditions 4% AgNO3 8% AgNO3
    15 minutes @ 65° C. 8.1 6.1
    15 minutes @ ambient 12.6 11.2
     4 hours @ ambient 8.0 9.0
  • From the above results, it was determined that higher concentrations of silver nitrate did not appear to be beneficial and that the use of a solution having a concentration of approximately 4% silver nitrate to produce a fibre having a silver content of 8% would give the optimum results. It was therefore decided to produce the master batch material using such a solution. [0026]
  • CMC tow or staple (50 g) was added to a solution of 4% silver nitrate (300 g) in industrial methylated spirit/water 50/50 at ambient temperature. The solution was held for convenience in a round screw top bottle so that it could be rolled on a laboratory bottle roller. The bottle was rolled for 15 minutes whereupon an ion exchange mechanism took place which produced silver containing CMC—referred to herein as silver CMC (8%w/w, Ag). [0027]
  • The spent silver nitrate solution was discarded and replaced with 50/50 industrial methylated spirit/water wash liquor (300 g) followed by shaking for five minutes. This washing process was repeated and finally a soft finish was used. This consisted of 0.5% polysorbate 20 (Tween) 20 in 90:10 industrial methylated spirit/water (i.e. 1.5 g in 300 g). [0028]
  • Excess liquor was squeezed out of the fibre, which was then allowed to dry at ambient temperature. The silver CMC tow was then opened out and spread onto an open bench to allow maximum access to light. The discolouring tow was handled periodically to expose new surfaces to the light. This was continued until the majority of the tow assumed a chocolate brown coloration (about two weeks). [0029]
  • The predominantly brown silver CMC tow produced was blended with untreated carboxymethyl cellulose (CMC) fibre at the ratios shown as follows to produce blends having 0.5%, 1.0% and 2.0% silver:[0030]
  • 6.25% silver CMC +93.75% CMC fibre=0.5% Ag
  • 12.5% silver CMC +87.50% CMC fibre=1.0% Ag
  • 25.0% silver CMC +75.00% CMC fibre=2.0% Ag
  • Blending was accomplished by carrying out a carding operation twice to achieve a uniform blend, on hand pre-mixed fibre. The carded web was then cross-folded to give the desired basis weight. The web was then bonded on a needle loom to give a coherent web from which individual dressings were cut. In addition, a conventional carboxymethyl cellulose fibre control sample was manufactured by the same method. [0031]
  • Absorbency Results [0032]
  • The master batch material was produced by the soaking of CMC fibre tow in silver nitrate and the absorbency tests were first of all carried out on tow using a free swell test. It was found that the CMC fibre control had an absorbency of 28 g/g and the silver CMC had an absorbency of 30 g/g. These differences were not considered to be significant. [0033]
  • Absorbency tests were then carried out on fabric produced by needle felting from fibres as above. [0034]
  • Fabric absorbencies as measured by the test identified in the British Pharmacopoeia 1993 Addendum 1995 page 1706, Alginate Dressing Absorbency were found to be as shown in the following table, in which gsm=grams per square metre and is a measure of the amount of fabric produced. [0035]
    gsm Absorbency g/g Absorbency g/piece
    CMC control 111  16.0 18.0
    0.5% silver CMC 99 20.0 19.5
    1.0% silver CMC 91 20.5 18.7
    2.0% silver CMC 65 22.3 14.5
  • As can be seen from the above table, the addition of silver was found to have very little effect on the absorbency, if anything increasing the absorbency on a gram per gram basis, though having less effect on absorbency on a gram per piece basis. [0036]
  • After wetting for 30 minutes in saline, the fabrics which were initially a fairly dark fawn, changed colour and became lighter and more translucent as time passed. [0037]
  • It appeared that there was no difference in the gelling properties between the CMC and the silver CMC, which is an important observation in that the silver addition does not destroy the valuable gelling properties. [0038]
  • Microbial Activity [0039]
  • To measure the efficiency of the silver containing material in reducing microbial activity, 250 g of milk was mixed with 0.2 g of fibre. The results were as follows: [0040]
    Control (milk alone) Malodour in 2 days
    Control (CMC in milk) Malodour in 2 days
    0.5% Silver (web) Malodour in 2 weeks
    8.0% Silver (tow) No Malodour in 3 weeks
  • These tests were repeated with 0.9 wt/. sodium chloride additions (chosen to be equivalent to the salt level in body fluids) to the milk, and the same results were obtained. This shows that the chloride ions in the salt were not detrimental to the antimicrobial properties of the silver in the silver CMC. [0041]
  • As can be seen from the above results, milk alone and milk containing CMC fibre alone went off in two days, as could be easily determined by the smell. By comparison, where the web contained 0.5% silver, there was a two week period before the milk went off and could be smelt. With unblended tow containing 8% silver, no smell could be detected after a three week period when the test was stopped. [0042]
  • In practice, the wound treatment products utilising the invention are unlikely to be left on a wound for more than a few days, and certainly no more than a week, so that it an be seen that a blend containing 0.5% silver retains its efficiency in terms of antimicrobial effect for at least twice the period that would be required in practice. [0043]
  • EXAMPLE 2
  • A solution of water (33.1 g) and industrial methylated spirit (IMS) (36.0 g) was made up in a black glass bottle suitable for rolling on a bottle roller. To it was added silver nitrate (30.0 g) and the latter was stirred until it dissolved. No heat was required. To this solution was added 12g of high manuronic calcium alginate tow and the whole was rolled on a bottle roller for four hours. After this period of time the tow was removed and washed in a solution (70 g) containing IMS and water as a 50/50 mixture. Soft finish in the form of polysorbate 20 (0.7 g) was dissolved in (70 g) solution of IMS/water as a 95/5 mixture and the tow was soaked in this medium for approximately 50 minutes. The silver alginate master batch was then dried in a fume cupboard to give a product having 13.7% of silver overall on the fibre. [0044]
  • 5 g of the above silver alginate master batch was weighed and cut into staple and opened by hand. 95 g of standard high manuronic calcium alginate fibre was also cut into staple and opened. The two were blended on the in-put feed belt of a laboratory carding machine. [0045]
  • The diluted silver alginate fibre was then carded, cross-folded and needled into a non-woven web. By calculation the final product would contain silver at an average level of 0.6%. It had a light grey-brown flecked mottled appearance. [0046]
  • In a comparative example, the same level (0.68%) of silver was applied uniformly to a batch of the same calcium alginate fibre, and it was then carded, cross-folded, and needled to form a nonwoven web. The web was exposed to light and developed a uniform darkish brown colour, appearing much darker than the mottled appearance of the blended web having the same average amount of silver present. [0047]
  • The invention also contemplates multiple layer dressings some or all of which layers may comprise blended product incorporated silver additions. For example, a silver containing blended layer of a non-gel forming fibre, such as a silver containing acrylic fibre blended with pure acrylic fibre could be faced with a wound contact layer of a gel forming fibre. An example of the contact layer could be an alginate fibre and the alginate layer could be blended with a silver added fibre or may have no silver at all, being a simple gel forming alginate fibre. [0048]

Claims (23)

1. A wound dressing having anti-microbial activity, which wound dressing comprises a first fibre capable of bonding with silver (1) cations, characterised in that the wound dressing comprises a blend of the first fibre to which silver (1) cations are bonded and a second fibre which is substantially free from silver.
2. A wound dressing according to claim 1 characterised in that it comprises from 0.01 to 5.0 percent by weight, of silver (1) cations based on the weight of fibre.
3. A wound dressing according to claim 2 characterised in that it comprises from 0.1 to 4.0 percent by weight of silver (1) cations based on the weight of fibre.
4. A wound dressing according to claim 3 characterised in that it comprises from 0.25 to 3.0 percent by weight of silver (1) cations based on the weight of fibre.
5. A wound dressing according to any of claims 1 to 4 characterised in that the first fibre is substantially insoluble in water.
6. A wound dressing according to any of claims 1 to 5 characterised in that the first fibre comprises a carboxymethylcellulose fibre, an alginate fibre, a chitosan or chitosan derivative fibre or an acrylic fibre.
7. A wound dressing according to claim 6 characterised in that the first fibre is a carboxymethyl cellulose fibre and the wound dressing contains from 1.0 to 2.0% by weight of silver (1) cations, based on the weight of the fibre.
8. A wound dressing according to claim 6 characterised in that the first fibre is an alginate fibre and the wound dressing contains from 0.25 to 0.75% by weight of silver (1) cations, based on the weight of the fibre.
9. A wound dressing according to claim 6 or claim 7 characterised in that the first fibre is a carboxymethylcellulose fibre which has a degree of substitution between 0.1 and 0.4.
10. A wound dressing according to claim 6 characterised in that the first fibre is an acrylic fibre which incorporates a comonomer to provide dye-sites in the fibre.
11. A wound dressing according to claim 10 characterised in that the comonomer isitaconic acid or 2-acrylomido methyl propane sulphonic acid.
12. A wound dressing according to any of claims 1 to 11 characterised in that the first fibre and the second fibre are similar.
13. A wound dressing according to any of claims 1 to 12 characterised in that the ratio of the first fibre to the second fibre is in the range of from 0.5 to 25% by weight of the total weight of the fibre.
14. A wound dressing according to claim 13 characterised in that the ratio of the first fibre to the second fibre is in the range of from 5 to 20% by weight of the total weight of the fibre.
15. A wound dressing according to any of claims 1 to 10 characterised in that the first fibre includes about 10% by weight, based on the weight of fibre, of silver (1) cations.
16. A wound dressing according to any of claims 1 to 12 characterised in that the silver ions are preferably chemically bonded to the first fibre.
17. A wound dressing according to any of claims 9 to 14 characterised in that the first fibre is a carboxymethylcellulose fibre and the degree of substitution is in the range from 0.20 to 0.35.
18. A wound dressing according to claim 14 characterised in that the degree of substitution is about 0.3.
19. A wound dressing according to any of claims 1 to 15 characterised in that the silver ions are introduced into the first fibre by ion-exchange.
20. A wound dressing according to any of claims 1 to 16 characterised in that the first fibre is a carboxymethylcellulose fibre and the carboxymethylcellulose is derived from lyocell.
21. A wound dressing according to any of claims 1 to 17 characterised in that the fibrous carboxymethylcellulose is in the form of a staple fibre or continuous filament yarn.
22. A wound dressing according to any one of the preceding claims characterised in that the carboxymethylcellulose is present in a needlepunched nonwoven textile.
23. A wound dressing substantially as herein described and with reference to the Example 5.
US10/311,674 2000-09-21 2001-09-21 Silver containing wound dressing Abandoned US20030180346A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US13/767,656 US8728513B2 (en) 2000-09-21 2013-02-14 Silver containing wound dressing
US14/280,512 US9066989B2 (en) 2000-09-21 2014-05-16 Silver containing wound dressing
US14/696,216 US9345805B2 (en) 2000-09-21 2015-04-24 Silver containing wound dressing
US15/162,890 US10010647B2 (en) 2000-09-21 2016-05-24 Silver containing wound dressing
US16/005,467 US10391197B2 (en) 2000-09-21 2018-06-11 Silver containing wound dressing

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0023155.5 2000-09-21
GB0023155A GB2370226A (en) 2000-09-21 2000-09-21 Wound dressing

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2001/004204 A-371-Of-International WO2002024240A1 (en) 2000-09-21 2001-09-21 Silver containing wound dressing

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/767,656 Continuation US8728513B2 (en) 2000-09-21 2013-02-14 Silver containing wound dressing

Publications (1)

Publication Number Publication Date
US20030180346A1 true US20030180346A1 (en) 2003-09-25

Family

ID=9899858

Family Applications (6)

Application Number Title Priority Date Filing Date
US10/311,674 Abandoned US20030180346A1 (en) 2000-09-21 2001-09-21 Silver containing wound dressing
US13/767,656 Expired - Fee Related US8728513B2 (en) 2000-09-21 2013-02-14 Silver containing wound dressing
US14/280,512 Expired - Lifetime US9066989B2 (en) 2000-09-21 2014-05-16 Silver containing wound dressing
US14/696,216 Expired - Lifetime US9345805B2 (en) 2000-09-21 2015-04-24 Silver containing wound dressing
US15/162,890 Expired - Fee Related US10010647B2 (en) 2000-09-21 2016-05-24 Silver containing wound dressing
US16/005,467 Expired - Lifetime US10391197B2 (en) 2000-09-21 2018-06-11 Silver containing wound dressing

Family Applications After (5)

Application Number Title Priority Date Filing Date
US13/767,656 Expired - Fee Related US8728513B2 (en) 2000-09-21 2013-02-14 Silver containing wound dressing
US14/280,512 Expired - Lifetime US9066989B2 (en) 2000-09-21 2014-05-16 Silver containing wound dressing
US14/696,216 Expired - Lifetime US9345805B2 (en) 2000-09-21 2015-04-24 Silver containing wound dressing
US15/162,890 Expired - Fee Related US10010647B2 (en) 2000-09-21 2016-05-24 Silver containing wound dressing
US16/005,467 Expired - Lifetime US10391197B2 (en) 2000-09-21 2018-06-11 Silver containing wound dressing

Country Status (11)

Country Link
US (6) US20030180346A1 (en)
EP (1) EP1318842B1 (en)
JP (1) JP4837878B2 (en)
AT (1) ATE270903T1 (en)
AU (2) AU8790601A (en)
CA (1) CA2420150C (en)
DE (1) DE60104320T2 (en)
ES (1) ES2223911T3 (en)
GB (1) GB2370226A (en)
PT (1) PT1318842E (en)
WO (1) WO2002024240A1 (en)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030176827A1 (en) * 2001-12-20 2003-09-18 Nobel Fiber Technologies Antibiotic textile materials suitable for wound dressings and wound dressings incorporating the same
US20040241213A1 (en) * 2001-09-12 2004-12-02 Roger Bray Antibacterial wound dressing
US20050123621A1 (en) * 2003-12-05 2005-06-09 3M Innovative Properties Company Silver coatings and methods of manufacture
US20050182347A1 (en) * 2004-02-13 2005-08-18 Bishop Stephen M. Multi layered wound dressing
US20060034899A1 (en) * 2004-08-12 2006-02-16 Ylitalo Caroline M Biologically-active adhesive articles and methods of manufacture
US20060211972A1 (en) * 2003-03-28 2006-09-21 Brian Nielsen Wound dressing
US20060233889A1 (en) * 2005-04-14 2006-10-19 3M Innovative Properties Company Silver coatings and methods of manufacture
EP1925719A1 (en) * 2006-09-21 2008-05-28 Alcare Co., Ltd. Antibacterial fiber, method for production of the fiber, antibacterial fiber product comprising the antibacterial fiber, method for production of the product, and method for reproduction of the product
US20080279960A1 (en) * 2006-01-13 2008-11-13 Burton Scott A Silver-Containing Antimicrobial Articles and Methods of Manufacture
US20100015208A1 (en) * 2008-03-19 2010-01-21 Bristol-Myers Squibb Company Antibacterial wound dressing
US20100098949A1 (en) * 2006-10-18 2010-04-22 Burton Scott A Antimicrobial articles and method of manufacture
WO2012058962A1 (en) 2010-11-03 2012-05-10 广东百合医疗科技有限公司 Antimicrobial fiber, fabric and wound dressing containing nano metal and preparation method thereof
WO2012155344A1 (en) * 2011-05-18 2012-11-22 河南天源环保高科股份有限公司 Fiber capable of absorbing iodine and preparation method and use thereof
WO2013159668A1 (en) 2012-04-23 2013-10-31 佛山市优特医疗科技有限公司 Silvery antibacterial fibre, texture, and wound dressing, and preparation method thereof
US20140308329A1 (en) * 2010-11-18 2014-10-16 Zeba Parkar Preservation of liquid foods
WO2014186590A1 (en) * 2013-05-15 2014-11-20 Convatec Technologies Inc. Wound dressing comprising an antimicrobial composition
US20150335492A1 (en) * 2012-12-28 2015-11-26 Foshan Medical Technologies, Ltd. Chemically modified seacell fibres, wound dressing made therefrom and preparation method thereof
US9440001B2 (en) 2013-03-06 2016-09-13 Specialty Fibres and Materials Limited Absorbent materials
US9907702B2 (en) 2011-08-17 2018-03-06 3M Innovative Properties Company Monomer-grafted fibers and uses thereof
US10493101B2 (en) 2005-12-14 2019-12-03 Convatec Technologies Inc. Antimicrobial composition
US11135315B2 (en) 2010-11-30 2021-10-05 Convatec Technologies Inc. Composition for detecting biofilms on viable tissues
US11286601B2 (en) 2012-12-20 2022-03-29 Convatec Technologies, Inc. Processing of chemically modified cellulosic fibres

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2370226A (en) 2000-09-21 2002-06-26 Acordis Speciality Fibres Ltd Wound dressing
GB2392913B (en) * 2002-09-11 2007-04-04 Johnson & Johnson Medical Ltd Wound dressings comprising complexes of oxidised celluloses with silver
CA2495541C (en) 2002-09-11 2011-07-12 Johnson & Johnson Medical Limited Wound dressing materials comprising complexes of anionic polysaccharides with silver
EP1901723B9 (en) * 2005-06-27 2011-09-14 Smith & Nephew, PLC Antimicrobial materials
JP2008546832A (en) 2005-06-27 2008-12-25 スミス アンド ネフュー ピーエルシー Antibacterial biguanide metal complex
ES2430688T3 (en) * 2005-10-21 2013-11-21 Argentum Medical, Llc Medical device
GB0523166D0 (en) 2005-11-15 2005-12-21 Lantor Uk Ltd Improvements in and relating to medical products
KR100788997B1 (en) * 2006-03-10 2007-12-28 김주영 Method For Preparing Silver Bonded Antimicrobial Moist Wound Dressing And The Moist Wound Dressing
US9221963B2 (en) 2008-11-27 2015-12-29 Speciality Fibres And Materials Ltd. Absorbent material
FI123878B (en) 2011-01-19 2013-11-29 Silvergreen Oy Ltd An antimicrobial wound dressing and method for its preparation
CN102743786B (en) 2011-04-20 2015-03-18 佛山市优特医疗科技有限公司 Wound dressing having bacteriostasis and hygroscopicity
CN103908693B (en) * 2014-04-15 2015-10-28 山东颐诺生物科技有限公司 A kind of bionic-type alginic acid base composite antibiotic dressing and preparation method thereof
KR101559815B1 (en) 2014-04-22 2015-10-14 한국생산기술연구원 Mass manufacturing method of carboxymethyl cellulose fabrics
WO2019018997A1 (en) 2017-07-25 2019-01-31 惠州华阳医疗器械有限公司 Antimicrobial alginate fibre, and preparation method for and use of dressing thereof
US10463760B2 (en) 2017-10-31 2019-11-05 InMEDBio, LLC Absorbent, breathable and pathogen blocking/killing wound care dressing and fabrication thereof
CN111601545B (en) 2017-11-09 2024-05-07 康沃特克科技公司 Ostomy monitoring system and method
USD893514S1 (en) 2018-11-08 2020-08-18 11 Health And Technologies Limited Display screen or portion thereof with graphical user interface
CN109453411B (en) * 2018-12-03 2021-11-26 广州润虹医药科技股份有限公司 Chitosan dressing
WO2021070915A1 (en) * 2019-10-10 2021-04-15 旭化成株式会社 Antibacterial sheet-like structure

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4306551A (en) * 1980-07-28 1981-12-22 Lectec Corporation Sterile improved bandage and sealant
US6087549A (en) * 1997-09-22 2000-07-11 Argentum International Multilayer laminate wound dressing
US6506873B1 (en) * 1997-05-02 2003-01-14 Cargill, Incorporated Degradable polymer fibers; preparation product; and, methods of use
US6605751B1 (en) * 1997-11-14 2003-08-12 Acrymed Silver-containing compositions, devices and methods for making

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5438951A (en) * 1977-08-29 1979-03-24 Toray Industries Fiber article with excellent sterilizing and water absorbing property
GB8609367D0 (en) 1986-04-17 1986-05-21 Johnson & Johnson Adhesive wound dressing
GB9001878D0 (en) 1990-01-26 1990-03-28 Beam Tech Ltd Alginate materials
GB9126193D0 (en) 1991-12-10 1992-02-12 Courtaulds Plc Cellulosic fibres
JP3049933B2 (en) * 1992-04-10 2000-06-05 松下電器産業株式会社 Deodorant cloth heater
JP3201023B2 (en) * 1992-11-17 2001-08-20 東亞合成株式会社 Manufacturing method of antibacterial synthetic fiber
ATE152784T1 (en) 1993-01-20 1997-05-15 Squibb & Sons Inc FIBERS
GB9301258D0 (en) 1993-01-22 1993-03-17 Courtaulds Plc Use of absorbent fibre
WO1994016746A1 (en) 1993-01-22 1994-08-04 Courtaulds Plc Wound dressings
GB9400994D0 (en) 1994-01-20 1994-03-16 Bristol Myers Squibb Co Wound dressing
JP3121503B2 (en) 1994-10-18 2001-01-09 レンゴー株式会社 Antibacterial agent
US5439915A (en) 1994-10-20 1995-08-08 American Home Products Corporation Pyrido[3,4-B]indole carboxamide derivatives as serotonergic agents
GB9421653D0 (en) * 1994-10-27 1994-12-14 Innovative Tech Ltd Wound dressing
JPH09256226A (en) * 1996-03-22 1997-09-30 Sakai Chem Ind Co Ltd Alginate fiber containing antimicrobial substance and its production
GB9618565D0 (en) * 1996-09-05 1996-10-16 Bristol Myers Co Wound dressing
FR2755613B1 (en) 1996-11-13 1999-01-08 Precis DRESSING MATERIAL HAVING CALCIUM ALGINATE MATRIX AND PROCESS FOR PRODUCING THE SAME
JPH111895A (en) 1997-04-17 1999-01-06 Rengo Co Ltd Sanitary article
JP3051709B2 (en) * 1997-09-30 2000-06-12 憲司 中村 Antimicrobial cellulose fiber and method for producing the same
JP4447066B2 (en) 1998-03-27 2010-04-07 キャタピラー インコーポレイテッド Hydraulic control device for work implement installation
JPH11319067A (en) * 1998-05-21 1999-11-24 Ribateepu Seiyaku Kk Film material and adhesive tape using the same
EP2036581B1 (en) 1998-07-01 2012-06-27 ConvaTec Limited Wound dressings and materials suitable for use therein
AU5153399A (en) * 1998-08-14 2000-03-06 Coloplast A/S Stabilised compositions having antibacterial activity
GB2370226A (en) 2000-09-21 2002-06-26 Acordis Speciality Fibres Ltd Wound dressing

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4306551A (en) * 1980-07-28 1981-12-22 Lectec Corporation Sterile improved bandage and sealant
US6506873B1 (en) * 1997-05-02 2003-01-14 Cargill, Incorporated Degradable polymer fibers; preparation product; and, methods of use
US6087549A (en) * 1997-09-22 2000-07-11 Argentum International Multilayer laminate wound dressing
US6605751B1 (en) * 1997-11-14 2003-08-12 Acrymed Silver-containing compositions, devices and methods for making

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040241213A1 (en) * 2001-09-12 2004-12-02 Roger Bray Antibacterial wound dressing
US8828424B2 (en) 2001-09-12 2014-09-09 Convatec Limited Antibacterial wound dressing
US10342890B2 (en) 2001-09-12 2019-07-09 Convatec Limited Antibacterial wound dressing
US20030176827A1 (en) * 2001-12-20 2003-09-18 Nobel Fiber Technologies Antibiotic textile materials suitable for wound dressings and wound dressings incorporating the same
US7385101B2 (en) * 2001-12-20 2008-06-10 Noble Fiber Technologies, Llc Antibiotic textile materials suitable for wound dressings and wound dressings incorporating the same
US20060211972A1 (en) * 2003-03-28 2006-09-21 Brian Nielsen Wound dressing
US20050123621A1 (en) * 2003-12-05 2005-06-09 3M Innovative Properties Company Silver coatings and methods of manufacture
US20050182347A1 (en) * 2004-02-13 2005-08-18 Bishop Stephen M. Multi layered wound dressing
US7759537B2 (en) * 2004-02-13 2010-07-20 Convatec Technologies Inc. Multi layered wound dressing
US20060034899A1 (en) * 2004-08-12 2006-02-16 Ylitalo Caroline M Biologically-active adhesive articles and methods of manufacture
US20060233889A1 (en) * 2005-04-14 2006-10-19 3M Innovative Properties Company Silver coatings and methods of manufacture
US8399027B2 (en) * 2005-04-14 2013-03-19 3M Innovative Properties Company Silver coatings and methods of manufacture
US10493101B2 (en) 2005-12-14 2019-12-03 Convatec Technologies Inc. Antimicrobial composition
US20080279960A1 (en) * 2006-01-13 2008-11-13 Burton Scott A Silver-Containing Antimicrobial Articles and Methods of Manufacture
US9289450B2 (en) 2006-01-13 2016-03-22 3M Innovative Properties Company Silver-containing antimicrobial articles and methods of manufacture
US8192764B2 (en) 2006-01-13 2012-06-05 3M Innovative Properties Company Silver-containing antimicrobial articles and methods of manufacture
EP1925719A4 (en) * 2006-09-21 2008-10-22 Alcare Co Ltd Antibacterial fiber, method for production of the fiber, antibacterial fiber product comprising the antibacterial fiber, method for production of the product, and method for reproduction of the product
US7858106B2 (en) 2006-09-21 2010-12-28 Alcare Co., Ltd. Antimicrobial fiber and its production method, and antimicrobial fiber product comprising the antimicrobial fiber, its production method and regeneration method
US20100113537A1 (en) * 2006-09-21 2010-05-06 Alcare Co., Ltd. Antimicrobial fiber and its production method, and antimicrobial fiber product comprising the antimicrobial fiber, its production method and regeneration method
EP1925719A1 (en) * 2006-09-21 2008-05-28 Alcare Co., Ltd. Antibacterial fiber, method for production of the fiber, antibacterial fiber product comprising the antibacterial fiber, method for production of the product, and method for reproduction of the product
US20100098949A1 (en) * 2006-10-18 2010-04-22 Burton Scott A Antimicrobial articles and method of manufacture
US8637072B2 (en) * 2008-03-19 2014-01-28 Convatec Technologies, Inc. Antimicrobial wound dressing comprising gel-forming fibers and specific ratio of silver to nitrate
EP2262545B1 (en) 2008-03-19 2019-10-09 ConvaTec Technologies Inc. Process for the manufacture of an antibacterial wound dressing
US20100015208A1 (en) * 2008-03-19 2010-01-21 Bristol-Myers Squibb Company Antibacterial wound dressing
WO2012058962A1 (en) 2010-11-03 2012-05-10 广东百合医疗科技有限公司 Antimicrobial fiber, fabric and wound dressing containing nano metal and preparation method thereof
US20140308329A1 (en) * 2010-11-18 2014-10-16 Zeba Parkar Preservation of liquid foods
US11135315B2 (en) 2010-11-30 2021-10-05 Convatec Technologies Inc. Composition for detecting biofilms on viable tissues
WO2012155344A1 (en) * 2011-05-18 2012-11-22 河南天源环保高科股份有限公司 Fiber capable of absorbing iodine and preparation method and use thereof
US9907702B2 (en) 2011-08-17 2018-03-06 3M Innovative Properties Company Monomer-grafted fibers and uses thereof
WO2013159668A1 (en) 2012-04-23 2013-10-31 佛山市优特医疗科技有限公司 Silvery antibacterial fibre, texture, and wound dressing, and preparation method thereof
US11286601B2 (en) 2012-12-20 2022-03-29 Convatec Technologies, Inc. Processing of chemically modified cellulosic fibres
US20150335492A1 (en) * 2012-12-28 2015-11-26 Foshan Medical Technologies, Ltd. Chemically modified seacell fibres, wound dressing made therefrom and preparation method thereof
US10603218B2 (en) * 2012-12-28 2020-03-31 Foshan United Medical Technologies, Ltd. Chemically modified seacell fibres, wound dressing made therefrom and preparation method thereof
US9440001B2 (en) 2013-03-06 2016-09-13 Specialty Fibres and Materials Limited Absorbent materials
CN105407930A (en) * 2013-05-15 2016-03-16 康沃特克科技公司 Wound dressing comprising an antimicrobial composition
WO2014186590A1 (en) * 2013-05-15 2014-11-20 Convatec Technologies Inc. Wound dressing comprising an antimicrobial composition

Also Published As

Publication number Publication date
US20180289852A1 (en) 2018-10-11
EP1318842A1 (en) 2003-06-18
WO2002024240A1 (en) 2002-03-28
CA2420150A1 (en) 2002-03-28
GB0023155D0 (en) 2000-11-01
JP4837878B2 (en) 2011-12-14
AU8790601A (en) 2002-04-02
US9345805B2 (en) 2016-05-24
US20150224223A1 (en) 2015-08-13
DE60104320D1 (en) 2004-08-19
CA2420150C (en) 2011-06-28
PT1318842E (en) 2004-11-30
EP1318842B1 (en) 2004-07-14
US10010647B2 (en) 2018-07-03
GB2370226A (en) 2002-06-26
DE60104320T2 (en) 2005-08-04
ES2223911T3 (en) 2005-03-01
ATE270903T1 (en) 2004-07-15
JP2004508895A (en) 2004-03-25
US9066989B2 (en) 2015-06-30
AU2001287906B2 (en) 2006-06-08
US8728513B2 (en) 2014-05-20
US10391197B2 (en) 2019-08-27
US20160263274A1 (en) 2016-09-15
US20130217649A1 (en) 2013-08-22
US20140256676A1 (en) 2014-09-11

Similar Documents

Publication Publication Date Title
US10391197B2 (en) Silver containing wound dressing
AU2001287906A1 (en) Silver containing wound dressing
KR101004280B1 (en) Antibacterial fiber, method for production of the fiber, antibacterial fiber product comprising the antibacterial fiber, method for production of the product, and method for reproduction of the product
US5856248A (en) Microbistatic and deodorizing cellulose fibers
EP0680344B1 (en) Wound dressings
EP2589393B1 (en) Wound care device
US7652189B2 (en) Carboxymethylated cellulosic wound dressing
EP2695622A1 (en) A chitosan wound dressing and its method of manufacturing
EP0905289A2 (en) Antibacterial cellulose fiber and production process thereof
CA2637251A1 (en) Antiseptic alginate preparation
JP4826382B2 (en) Antibacterial cellulose fiber and textile product for skin contact
WO2001092632A1 (en) Fiber product having antibacterial and deodorant function
KR20050103923A (en) Disposable feminine hygiene products
EP4087549A1 (en) Antimicrobial fibres
JPH055274A (en) Anti-skin inflammatory, antimicrobial, antimycotic and deodorant nonwoven fabric of staple fiber having hydrophilic nature

Legal Events

Date Code Title Description
AS Assignment

Owner name: ACORDIS SPECIALITY FIBRES LIMITED, UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:WOODS, DAVID MALCOLM;REEL/FRAME:013973/0803

Effective date: 20021104

AS Assignment

Owner name: CONVATEC LIMITED,UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ACORDIS SPECIALITY FIBRES LIMITED;REEL/FRAME:018375/0095

Effective date: 20050610

Owner name: CONVATEC LIMITED, UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ACORDIS SPECIALITY FIBRES LIMITED;REEL/FRAME:018375/0095

Effective date: 20050610

AS Assignment

Owner name: J.P. MORGAN EUROPE LIMITED, UNITED KINGDOM

Free format text: SECURITY AGREEMENT;ASSIGNOR:CONVATEC LIMITED;REEL/FRAME:021901/0518

Effective date: 20081028

Owner name: J.P. MORGAN EUROPE LIMITED,UNITED KINGDOM

Free format text: SECURITY AGREEMENT;ASSIGNOR:CONVATEC LIMITED;REEL/FRAME:021901/0518

Effective date: 20081028

AS Assignment

Owner name: CONVATEC LIMITED, UNITED KINGDOM

Free format text: RELEASE OF SECURITY INTEREST AT 021901/0518;ASSIGNOR:J.P. MORGAN EUROPE LIMITED;REEL/FRAME:025581/0062

Effective date: 20101223

AS Assignment

Owner name: JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT, TE

Free format text: SECURITY AGREEMENT;ASSIGNOR:CONVATEC LIMITED;REEL/FRAME:025591/0711

Effective date: 20101222

AS Assignment

Owner name: JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT, TE

Free format text: AMENDED AND RESTATED SECURITY AGREEMENT;ASSIGNOR:CONVATEC LIMITED;REEL/FRAME:027024/0681

Effective date: 20110926

STCB Information on status: application discontinuation

Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION

AS Assignment

Owner name: CONVATEC LIMITED, UNITED KINGDOM

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:JPMORGAN CHASE BANK, N.A.;REEL/FRAME:040543/0357

Effective date: 20161031

Owner name: UNOMEDICAL LIMITED, UNITED KINGDOM

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:JPMORGAN CHASE BANK, N.A.;REEL/FRAME:040543/0357

Effective date: 20161031

Owner name: UNOMEDICAL A/S, DENMARK

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:JPMORGAN CHASE BANK, N.A.;REEL/FRAME:040543/0357

Effective date: 20161031

Owner name: CONVATEC TECHNOLOGIES, INC., NEVADA

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:JPMORGAN CHASE BANK, N.A.;REEL/FRAME:040543/0357

Effective date: 20161031